This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists, super agonists, full agonists, or partial agonists.
dihydroanthracene-based tetratopic linkers as building blocks. Structural analysis reveals that these frameworks are all two-dimensional but comprise three distinct connectivities of Zr6 nodes. By using the steric hindrance of the nonplanar linker, the connectivity of Zr6 node can be tuned from 8-c to unusual 4-c. Further, through either one-pot synthesis or postsyntheticlinker installation strategies, the
Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors
申请人:——
公开号:US20040266826A1
公开(公告)日:2004-12-30
A compound of the formula: in which R
1
is optionally substituted phenyl, optionally substituted naphthyl, optionally substituted bicyclic heterocyclic group, optionally substituted lower alkenyl or optionally substituted lower alkynyl, and R
2
is carboxy or protected carboxy, or a salt thereof, useful for treating and/or preventing MMP- or TNF-&agr; mediated diseases.
1
nonsymmetric organic linker. HIAM-4017 exhibits high porosity and excellent chemical and thermalstability. Furthermore, excited-state intramolecular proton transfer (ESIPT) was achieved in an isoreticular MOF, HIAM-4018, with a large Stokes shift of 155 nm as a result of introducing the hydroxyl group to the linker skeleton to induce OH···N interactions. Such interactions were analyzed thoroughly by employing